Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Maze Therapeutics, Inc. - Common Stock (NQ:MAZE)

32.50 +1.24 (+3.97%)

Streaming Delayed Price Updated: 2:46 PM EDT, Jul 6, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	282,090
Open	31.25
Bid (Size)	32.38 (300)
Ask (Size)	32.50 (100)
Prev. Close	31.26
Today's Range	31.01 - 32.51
52wk Range	11.34 - 53.65
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors? ↗

June 29, 2026

This clinical-stage biotech targeting kidney and metabolic diseases reported a notable insider sale, recent filings show.

Via The Motley Fool

Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors? ↗

June 05, 2026

This clinical-stage biotech advancing precision medicines reported a notable insider sale amid strong one-year share performance.

Via The Motley Fool

Performance

YTD	-18.3%	-18.3%
1 Month	+33.9%	+33.9%
3 Month	+12.1%	+12.1%
6 Month	-15.9%	-15.9%
1 Year	+168.2%	+168.2%

More News

Maze Therapeutics to Participate in Two Upcoming Investor Conferences

May 27, 2026

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗

May 17, 2026

Via The Motley Fool

Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

May 12, 2026

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials ↗

May 07, 2026

Via The Motley Fool

Maze Therapeutics Announces $150 Million Registered Offering

April 22, 2026

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. ↗

April 04, 2026

Via The Motley Fool

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

March 25, 2026

Via Chartmill

Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33% ↗

March 25, 2026

Via The Motley Fool

Wednesday's session: top gainers and losers ↗

March 25, 2026

Via Chartmill

Which stocks are gapping on Wednesday? ↗

March 25, 2026

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

March 25, 2026

Via Chartmill

Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

March 25, 2026

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

March 25, 2026

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears ↗

March 21, 2026

Via The Motley Fool

Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

February 25, 2026

From Maze Therapeutics, Inc.

Via GlobeNewswire

Marc Andreessen’s a16z Invests $465 Million in Navan’s Corporate Spending Platform, According to Recent SEC Filing ↗

February 18, 2026

Via The Motley Fool

Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge ↗

February 16, 2026

Via The Motley Fool

Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

February 04, 2026

From Maze Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock ↗

February 01, 2026

Via The Motley Fool

What to Know About One Maze Insider's $3 Million Stock Sale as Shares Surge 150% ↗

January 07, 2026

Via The Motley Fool

Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Maze Therapeutics, Inc.

Via GlobeNewswire

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗

December 08, 2025

Via The Motley Fool

Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

November 06, 2025

From Maze Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Maze Therapeutics, Inc. - Common Stock publicly traded?

Yes, Maze Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Maze Therapeutics, Inc. - Common Stock trade on?

Maze Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Maze Therapeutics, Inc. - Common Stock?

The ticker symbol for Maze Therapeutics, Inc. - Common Stock is MAZE on the Nasdaq Stock Market

What is the current price of Maze Therapeutics, Inc. - Common Stock?

The current price of Maze Therapeutics, Inc. - Common Stock is 32.50

When was Maze Therapeutics, Inc. - Common Stock last traded?

The last trade of Maze Therapeutics, Inc. - Common Stock was at 07/06/26 02:46 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.